Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for quality of life in patients with heart failure
IRCT20111206008307N38Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Feb 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of colchicine in heart failure (HF) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Change in serum inflammatory factor levels and Change in quality of life. Started Feb 2022; status: completed.
02
Drugs
colchicine
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on IRCT20111206008307N38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20111206008307N38.